U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H7N3O5
Molecular Weight 225.1583
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of FURAZOLIDONE

SMILES

[O-][N+](=O)C1=CC=C(O1)\C=N\N2CCOC2=O

InChI

InChIKey=PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+

HIDE SMILES / InChI
Molecular Formula C8H7N3O5
Molecular Weight 225.1583
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: http://www.ncbi.nlm.nih.gov/pubmed/8030368

Furazolidone is a nitrofuran derivarive with broad antibacterial, antiprotazoal properties. It was used for the treatment of bacterial or protozoal enteritis and diarrhea, but now the drug is no longer prescibed in the US. The mechanism of furazolidone action is supposed to be mediated by its binding to bacterial DNA.

Originator

Approval Year

1957
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Target ID: CHEMBL2364041
Crosslinking Agent
81
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
FUROXONE

Approved Use

Unknown

Launch Date

-2.77171208E11
Curative
Approved
8429
FUROXONE

Approved Use

Unknown

Launch Date

-2.77171208E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.34 μg/mL
EXPERIMENT
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.0306-5251.2001.01435.x
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FURAZOLIDONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.89 μg × h/mL
EXPERIMENT
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.0306-5251.2001.01435.x
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FURAZOLIDONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.87 h
EXPERIMENT
https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.0306-5251.2001.01435.x
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FURAZOLIDONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, t.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
unhealthy, 18-79
n = 108
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 18-79
Sex: M+F
Population Size: 108
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
Disc. AE: Allergic skin reaction...
AEs leading to
discontinuation/dose reduction:
Allergic skin reaction (0.96%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, t.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
unhealthy, 21-79
n = 104
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 21-79
Sex: M+F
Population Size: 104
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
Disc. AE: Anaphylaxis...
AEs leading to
discontinuation/dose reduction:
Anaphylaxis (0.96%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
lansoprazole, p.o(30 mg, q.d.)
tetracycline, p.o(500 mg, q.i.d.)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16127567
Page: p.113
unhealthy, 42
n = 52
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42
Sex: M+F
Population Size: 52
Sources:
https://pubmed.ncbi.nlm.nih.gov/16127567
Page: p.113
Disc. AE: Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea
Sources:
https://pubmed.ncbi.nlm.nih.gov/16127567
Page: p.113
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, b.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
unhealthy, 42.3 (± 14.31)
n = 124
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42.3 (± 14.31)
Sex: M+F
Population Size: 124
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
Disc. AE: Headache, Vomiting...
AEs leading to
discontinuation/dose reduction:
Headache (severe)
Vomiting
Urticaria
Fever
Orthostatic dysregulation (severe)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
AEs

AEs

AESignificanceDosePopulation
Allergic skin reaction 0.96%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, t.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
unhealthy, 18-79
n = 108
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 18-79
Sex: M+F
Population Size: 108
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
Anaphylaxis 0.96%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, t.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
unhealthy, 21-79
n = 104
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 21-79
Sex: M+F
Population Size: 104
Sources:
https://pubmed.ncbi.nlm.nih.gov/23376004
Page: p.2, p.7
Nausea Disc. AE
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
lansoprazole, p.o(30 mg, q.d.)
tetracycline, p.o(500 mg, q.i.d.)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16127567
Page: p.113
unhealthy, 42
n = 52
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42
Sex: M+F
Population Size: 52
Sources:
https://pubmed.ncbi.nlm.nih.gov/16127567
Page: p.113
Fever Disc. AE
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, b.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
unhealthy, 42.3 (± 14.31)
n = 124
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42.3 (± 14.31)
Sex: M+F
Population Size: 124
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
Urticaria Disc. AE
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, b.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
unhealthy, 42.3 (± 14.31)
n = 124
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42.3 (± 14.31)
Sex: M+F
Population Size: 124
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
Vomiting Disc. AE
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, b.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
unhealthy, 42.3 (± 14.31)
n = 124
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42.3 (± 14.31)
Sex: M+F
Population Size: 124
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
Headache severe
Disc. AE
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, b.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
unhealthy, 42.3 (± 14.31)
n = 124
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42.3 (± 14.31)
Sex: M+F
Population Size: 124
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
Orthostatic dysregulation severe
Disc. AE
200 mg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Co-administed with::
amoxicillin, p.o(1000 mg, b.i.d)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
unhealthy, 42.3 (± 14.31)
n = 124
Health Status: unhealthy
Condition: Helicobacter pylori infections
Age Group: 42.3 (± 14.31)
Sex: M+F
Population Size: 124
Sources:
https://pubmed.ncbi.nlm.nih.gov/26157713
Page: p.5
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
UGT1A8
36

UGT1A10
32
CYP1A1
108
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
UGT1A10
41
 weak
UGT1A8
48
 weak
CYP1A1
218
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5195
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5195
MolPort
MolPort-006-110-177
https://www.molport.com/shop/molecule-link/MolPort-006-110-177
ZINC
ZINC000250090469
http://zinc15.docking.org/substances/ZINC000250090469
eMolecules
36495922
https://www.emolecules.com/cgi-bin/more?vid=36495922
PubMed

PubMed

TitleDatePubMed
[Methods of treatment of puerperal endometritis in cows].
1975
[Peripheral neuropathy due to furazolidone].
1975 Aug 1
Cholestatic hepatitis after administration of furan derivatives.
1975 May
Monoamine oxidase inhibition and furazolidone-induced cardiomyopathy in turkey poults.
1983 Sep
Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.
1991 Jan
Generation of furazolidone radical anion and its inhibition by glutathione.
1992 Aug
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Clinical pathologic profiles of dogs and turkeys with congestive heart failure, either noninduced or induced by rapid ventricular pacing, and turkeys with furazolidone toxicosis.
1993 Jan
[The effect of nitrofurazone and furazolidone on induction of cytochrome P-450 in the CYPIA test].
1995
Experimental furazolidone toxicosis in broiler chicks: effect of dosage, duration and age upon clinical signs and some blood parameters.
1995
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
Furazolidone-induced mood disorder during the treatment of refractory giardiasis in a patient with AIDS.
1998 Apr
One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
2001 Dec
Effects of furazolidone, PCB77, PCB126, Aroclor 1248, paraquat and p,p'-DDE on transketolase activity in embryonal chicken brain.
2002 May 1
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.
2012 Apr
Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells.
2013 Dec

Sample Use Guides

In Vivo Use Guide
One 100-mg tablet four times daily (adults), 25 to 50 mg four times daily (children).
Route of Administration: Oral
In Vitro Use Guide
The in vitro susceptibilities of 50 strains of Salmonella spp., 80 strains of Shigella spp., and 50 enterotoxigenic Escherichia coli, 14 Yersinia enterocolitica, 6 Aeromonas hydrophila, 4 Plesiomonas shigelloides, 9 Vibrio parahaemolyticus, and 30 Campylobacter jejuni strains that were recently isolated from worldwide sources were determined for furazolidone. MICs values were about 0.5-2 ug/ml (Salmonella spp.), 0.5-4 ug/ml (Shigella spp.), 16-128 ug/ml (Y. enterocolitica), 0.5-1 ug/ml (A. hydrophila, V. parahaemolyticus),0.5 ug/ml (P. shigelloides, C. jejuni).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:13:02 UTC 2023
Edited
by admin
on Fri Dec 15 16:13:02 UTC 2023
Record UNII
5J9CPU3RE0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FURAZOLIDONE
GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
FURAZOLIDONE [USP-RS]
Common Name English
Furazolidone [WHO-DD]
Common Name English
NIFURAZOLIDONE
Common Name English
FURAZOLIDONE [HSDB]
Common Name English
FURAZOLIDONE [ORANGE BOOK]
Common Name English
FURAZOLIDONE [GREEN BOOK]
Common Name English
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
Systematic Name English
FURAZOLIDONE [MI]
Common Name English
furazolidone [INN]
Common Name English
2-OXAZOLIDINONE, 3-(((5-NITRO-2-FURANYL)METHYLENE)AMINO)-
Systematic Name English
FUROXONE
Brand Name English
FURAZOLIDONE [USP MONOGRAPH]
Common Name English
FURAZOLIDONE [IARC]
Common Name English
FURAZOLIDONE [USP IMPURITY]
Common Name English
FURAZOLIDONE [MART.]
Common Name English
NSC-6469
Code English
Classification Tree Code System Code
IARC Furazolidone
CFR 21 CFR 524.1005
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
WHO-ATC G01AX06
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
WHO-VATC QG01AX06
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
WHO-VATC QJ01XE90
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
NCI_THESAURUS C254
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
CFR 21 CFR 530.41
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
Code System Code Type Description
PUBCHEM
5323714
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
RS_ITEM_NUM
1286800
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
MERCK INDEX
m5600
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID4041997
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
EVMPD
SUB07834MIG
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
NSC
6469
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
INN
273
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
ChEMBL
CHEMBL1103
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
SMS_ID
100000080696
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
NCI_THESAURUS
C65783
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
WIKIPEDIA
Furazolidone
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
DRUG CENTRAL
1257
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
DRUG BANK
DB00614
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
FDA UNII
5J9CPU3RE0
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
MESH
D005664
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
HSDB
7036
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
RXCUI
4601
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
200-653-3
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
CAS
67-45-8
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
CHEBI
5195
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
DAILYMED
5J9CPU3RE0
Created by admin on Fri Dec 15 16:13:02 UTC 2023 , Edited by admin on Fri Dec 15 16:13:02 UTC 2023
PRIMARY
Related Record Type Details
Structure of FURAZOLIDONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966